- Home
- SNTI vs RNXT Comparison
SNTI vs RNXT Comparison
Compare SNTI & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- RNXT
- Stock Information
- Founded
- SNTI 2016
- RNXT 2012
- Country
- SNTI United States
- RNXT United States
- Employees
- SNTI N/A
- RNXT N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- RNXT Health Care
- Exchange
- SNTI Nasdaq
- RNXT Nasdaq
- Market Cap
- SNTI 39.6M
- RNXT 44.6M
- IPO Year
- SNTI N/A
- RNXT 2021
- Fundamental
- Price
- SNTI $1.37
- RNXT $1.22
- Analyst Decision
- SNTI Strong Buy
- RNXT Strong Buy
- Analyst Count
- SNTI 2
- RNXT 2
- Target Price
- SNTI $8.50
- RNXT $7.50
- AVG Volume (30 Days)
- SNTI 120.0K
- RNXT 646.9K
- Earning Date
- SNTI 11-13-2025
- RNXT 11-12-2025
- Dividend Yield
- SNTI N/A
- RNXT N/A
- EPS Growth
- SNTI N/A
- RNXT N/A
- EPS
- SNTI N/A
- RNXT N/A
- Revenue
- SNTI N/A
- RNXT $662,000.00
- Revenue This Year
- SNTI N/A
- RNXT $2,988.37
- Revenue Next Year
- SNTI $150.00
- RNXT $300.60
- P/E Ratio
- SNTI N/A
- RNXT N/A
- Revenue Growth
- SNTI N/A
- RNXT N/A
- 52 Week Low
- SNTI $1.26
- RNXT $0.75
- 52 Week High
- SNTI $16.94
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- SNTI 37.01
- RNXT 55.80
- Support Level
- SNTI $1.33
- RNXT $1.19
- Resistance Level
- SNTI $1.39
- RNXT $1.45
- Average True Range (ATR)
- SNTI 0.08
- RNXT 0.12
- MACD
- SNTI 0.01
- RNXT 0.02
- Stochastic Oscillator
- SNTI 31.43
- RNXT 54.90
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.